Lupin to Launch Vonoprazan Tablets in India under Patent Agreement with Takeda

Lupin Ltd has signed a non-exclusive patent licence agreement with Takeda Pharmaceutical to commercialize Vonoprazan tablets in India. The medication, which will be marketed as Lupivon, is approved to treat various gastrointestinal conditions. This collaboration aims to strengthen Lupin's gastroenterology portfolio.

Home-grown pharma major Lupin Ltd on Wednesday announced its entry into a non-exclusive patent licence agreement with Takeda Pharmaceutical Company Ltd to commercialize Vonoprazan tablets in the Indian market.

This agreement grants Lupin the rights to market Vonoprazan, a novel gastrointestinal drug, under the brand name Lupivon. The drug will be available in two strengths — 10 mg and 20 mg.

Rajeev Sibal, Lupin's President of India Region Formulations, noted that Vonoprazan offers a groundbreaking treatment for acid peptic disorders. He further stated that this collaboration aligns with Lupin's commitment to bring innovative medicines to meet the unmet needs of patients.

In India, Vonoprazan is approved by the Drugs Controller General of India (DCGI) for conditions such as reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment.

(With inputs from agencies.)